David J Chung

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York The Rockefeller University, New York, New York Weill Cornell Medical College, New York, New York
    Cancer Immunol Res 4:61-71. 2016
  2. pmc Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, New York, NY, USA
    J Transl Med 11:166. 2013
  3. pmc Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
    David J Chung
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Blood 114:555-63. 2009
  4. pmc Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
    Shane A Curran
    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York
    Cancer Immunol Res . 2016
  5. doi request reprint Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
    Gunjan L Shah
    a Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma . 2017
  6. doi request reprint Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation
    Heather Landau
    a Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 57:1781-5. 2016
  7. pmc Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA
    Blood 119:5182-90. 2012
  8. pmc CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma
    Eric Smith
    Hematology Oncology BMT Fellowship Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York
    Biol Blood Marrow Transplant 22:258-67. 2016
  9. pmc Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
    Kazunori Murata
    Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States Electronic address
    Clin Biochem . 2016
  10. ncbi request reprint Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency
    Adebayo Ogunniyi
    a Department of Pharmacy, Weill Cornell Medical College, New York, NY, USA
    Leuk Lymphoma . 2016

Collaborators

  • Guenther Koehne
  • Heather Landau
  • Sergio A Giralt
  • Emanuela Romano
  • Brian C Betts
  • Sundar Jagannath
  • David H Munn
  • CHRISTIAN MUNZ
  • Nikoletta Lendvai
  • Hani Hassoun
  • Ola Landgren
  • Alexander M Lesokhin
  • Gunjan L Shah
  • Satyajit Kosuri
  • Sean M Devlin
  • Shane A Curran
  • Eric Smith
  • Kazunori Murata
  • Sham Mailankody
  • Adebayo Ogunniyi
  • Sean Devlin
  • Suresh C Jhanwar
  • Ross Levine
  • Dory Londono
  • Nelly Adel
  • Neha S Korde
  • Glenn Heller
  • Samuel I McCash
  • Katharine C Hsu
  • Lakshmi V Ramanathan
  • Evelyn Orlando
  • James W Young
  • Alex M Lesokhin
  • Justin A Shyer
  • Sneh Sharma
  • Brittany Carroll
  • Ajai Chari
  • Mabel Rodriguez
  • Lilian Reich
  • Lillian R Talbot
  • Neha Korde
  • Alexander Lesokhin
  • Erin T St Angelo
  • Ioanna Tsakos
  • Patrick Hilden
  • Kaitlyn Redling
  • Wendy L Schaffer

Detail Information

Publications12

  1. pmc T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York The Rockefeller University, New York, New York Weill Cornell Medical College, New York, New York
    Cancer Immunol Res 4:61-71. 2016
    ..Collectively, these results identify T-cell exhaustion/senescence as a distinguishing feature of relapse and support early introduction of immunotherapy to stimulate antitumor immunity after ASCT...
  2. pmc Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, New York, NY, USA
    J Transl Med 11:166. 2013
    ..A detailed comparative evaluation of the effects of mRNA electroporation on LCs versus moDCs, however, is needed...
  3. pmc Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
    David J Chung
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Blood 114:555-63. 2009
    ....
  4. pmc Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade
    Shane A Curran
    Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York
    Cancer Immunol Res . 2016
    ..Cancer Immunol Res; 5(1); 1-9. ©2016 AACR...
  5. doi request reprint Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation
    Gunjan L Shah
    a Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma . 2017
    ..Overall, gain of 1q portends worse PFS and OS which was not negated by auto HCT. Such patients will likely require additional therapy to improve their survival...
  6. doi request reprint Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation
    Heather Landau
    a Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 57:1781-5. 2016
    ..We conclude that fractionated stem cell infusions following high-dose melphalan do not enhance engraftment kinetics or significantly alter patients' clinical course following AHCT in PCM. ..
  7. pmc Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA
    Blood 119:5182-90. 2012
    ..These data support the use of mRNA-electroporated LCs, or moDCs supplemented with exogenous rhuIL-15, as vaccines for cancer immunotherapy to break tolerance against self-differentiation antigens shared by tumors...
  8. pmc CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma
    Eric Smith
    Hematology Oncology BMT Fellowship Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York
    Biol Blood Marrow Transplant 22:258-67. 2016
    ..This study demonstrates notable safety and efficacy of CD34-selected HSCT in patients with multiply relapsed MM, including those with high-risk cytogenetics. ..
  9. pmc Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
    Kazunori Murata
    Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States Electronic address
    Clin Biochem . 2016
    ....
  10. ncbi request reprint Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency
    Adebayo Ogunniyi
    a Department of Pharmacy, Weill Cornell Medical College, New York, NY, USA
    Leuk Lymphoma . 2016
    ..019), as risk factors for low efficiency by multivariate analysis. This study demonstrates that P + G-CSF is highly efficient in MM patients and provides strong support for its upfront use in SC collection for MM patients...
  11. pmc Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, USA
    Clin Cancer Res 17:1984-97. 2011
    ..We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic cells (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity...
  12. pmc A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Nikoletta Lendvai
    Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Weill Medical College of Cornell University, New York, NY and
    Blood 124:899-906. 2014
    ..Seven patients (16%) discontinued treatment due to AEs. Carfilzomib 56 mg/m(2) ± dexamethasone was tolerable and provided durable responses. This trial was registered at www.clinicaltrials.gov as #NCT01351623. ..